Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 3.3% – What’s Next?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price was up 3.3% during trading on Wednesday . The company traded as high as $56.74 and last traded at $54.4380. 132,644 shares were traded during mid-day trading, a decline of 65% from the average daily volume of 382,722 shares. The stock had previously closed at $52.69.

Analyst Upgrades and Downgrades

PLSE has been the subject of a number of research reports. BTIG Research started coverage on Pulse Biosciences in a report on Wednesday. They set a “buy” rating and a $70.00 target price for the company. Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research report on Sunday, September 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They issued a “buy” rating and a $58.00 target price on the stock. Finally, Oppenheimer reissued an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pulse Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $50.20.

Pulse Biosciences Stock Up 1.0%

The firm has a market cap of $3.77 billion, a price-to-earnings ratio of -45.11 and a beta of 1.63. The business has a 50 day moving average price of $43.94 and a 200-day moving average price of $30.75.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 94.42% and a negative net margin of 6,755.78%.The company had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Research analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Insider Activity at Pulse Biosciences

In other news, COO Liane Teplitsky bought 1,036 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the completion of the purchase, the chief operating officer owned 1,036 shares of the company’s stock, valued at $49,966.28. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 4,095 shares of company stock worth $199,931 over the last 90 days. Insiders own 74.00% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors have recently added to or reduced their stakes in PLSE. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences during the second quarter worth $28,000. Jupiter Topco LLC acquired a new position in Pulse Biosciences during the 2nd quarter valued at about $241,000. GSA Capital Partners LLP bought a new position in Pulse Biosciences in the 2nd quarter worth about $290,000. Legal & General Group Plc acquired a new stake in shares of Pulse Biosciences in the second quarter valued at approximately $395,000. Finally, Cetera Investment Advisers acquired a new stake in shares of Pulse Biosciences in the first quarter valued at approximately $387,000. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a medical technology company developing proprietary bioelectric therapies based on its Nano-Pulse Stimulation technology. The platform delivers ultrashort electrical pulses designed to affect targeted cells while limiting thermal damage to surrounding noncellular tissue.

The company’s primary product is the CellFX System, which is designed to deliver Nano-Pulse Stimulation treatments for certain dermatological conditions. Pulse Biosciences is also developing additional applications for its technology in areas including cardiac procedures and other medical specialties.

Pulse Biosciences was founded in 2014 and is headquartered in Hayward, California.